Indian Journal of Urology Users online:1875  
IJU
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size

    Article Cited by others

ORIGINAL ARTICLE

A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer

Vijjan Vivek, Mandhani Anil, Kapoor Rakesh, Dubey Deepak, Srivastava Aneesh, Ansari M S, Singh Pratipal, Kumar Anant

Year : 2006| Volume: 22| Issue : 4 | Page no: 317-321

   This article has been cited by
 
1 XRCC1 codon 399 mutant allele: A risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy
Mittal, R.D., Singh, R., Manchanda, P.K., Ahirwar, D., Gangwar, R., Kesarwani, P., Mandhani, A.
Cancer Biology and Therapy. 2008; 7(5): 647-652
[Pubmed]  [Google Scholar]
2 Bacillus Calmette-Guerin in the management of superficial bladder cancer
Kapoor, R., Vijjan, V., Singh, P.
Indian Journal of Urology. 2008; 24(1): 72-76
[Pubmed]  [Google Scholar]
3 The Safety and Efficacy of Different Doses of Bacillus Calmette Guérin in Superficial Bladder Transitional Cell Carcinoma
Agrawal, M.S. and Agrawal, M. and Bansal, S. and Agarwal, M. and Lavania, P. and Goyal, J.
Urology. 2007; 70(6): 1075-1078
[Pubmed]  [Google Scholar]
4 The Safety and Efficacy of Different Doses of Bacillus Calmette Guérin in Superficial Bladder Transitional Cell Carcinoma
Madhu S. Agrawal,Moneet Agrawal,Sumit Bansal,Mayank Agarwal,Prashant Lavania,Jitendra Goyal
Urology. 2007; 70(6): 1075
[Pubmed]  [Google Scholar] [DOI]

 

Read this article
HEALTHWARE INDIA